FRG Family Wealth Advisors LLC Trims Position in Eli Lilly and Company (NYSE:LLY)

FRG Family Wealth Advisors LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 8,287 shares of the company's stock after selling 458 shares during the period. Eli Lilly and Company comprises about 1.2% of FRG Family Wealth Advisors LLC's holdings, making the stock its 20th biggest holding. FRG Family Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $6,398,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the stock. Principal Financial Group Inc. raised its holdings in Eli Lilly and Company by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after acquiring an additional 60,306 shares during the last quarter. Kovitz Investment Group Partners LLC grew its holdings in Eli Lilly and Company by 117.1% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 46,132 shares of the company's stock valued at $41,000 after buying an additional 24,879 shares in the last quarter. Wilson & Boucher Capital Management LLC boosted its holdings in Eli Lilly and Company by 15.8% in the 3rd quarter. Wilson & Boucher Capital Management LLC now owns 740 shares of the company's stock valued at $656,000 after purchasing an additional 101 shares during the last quarter. Sunbelt Securities Inc. increased its stake in Eli Lilly and Company by 9.6% during the third quarter. Sunbelt Securities Inc. now owns 5,453 shares of the company's stock worth $4,831,000 after acquiring an additional 477 shares during the last quarter. Finally, Fortem Financial Group LLC raised its position in Eli Lilly and Company by 23.7% in the third quarter. Fortem Financial Group LLC now owns 2,038 shares of the company's stock valued at $1,806,000 after purchasing an additional 390 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research report on Thursday, January 16th. Truist Financial increased their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Finally, Guggenheim dropped their target price on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research report on Monday. Two analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,012.00.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

LLY stock traded up $13.83 during trading on Monday, hitting $746.24. The company had a trading volume of 1,638,335 shares, compared to its average volume of 3,379,630. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The firm has a 50-day moving average price of $837.05 and a 200-day moving average price of $822.87. The firm has a market cap of $707.56 billion, a PE ratio of 63.73, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.